VIDEO: Tremfya ‘going to be a real player’ in treatment of CD, expert predicts
Click Here to Manage Email Alerts
Tremfya effectively induced clinical and corticosteroid-free remission among patients with moderate to severe Crohn’s disease, according to a presentation at the Congress of European Crohn’s and Colitis Organization.
While not currently approved to treat CD in the United States, phase 3 trials evaluating the safety and efficacy of Tremfya (guselkumab, Janssen) are ongoing and actively enrolling participants.
“Guselkumab is going to be effective not only as an induction therapy, as was seen in the week 12 results, but also through subcutaneous maintenance dosing and all the way out to week 48,” Bruce Sands, MD, of the Icahn School of Medicine at Mount Sinai New York, said in a Healio video exclusive. “I think this drug is going to be a real player for the treatment of Crohn's disease.”
Collapse
Sands B, et al. Abstract OP24. Presented at: Congress of European Crohn’s and Colitis Organization; Feb. 16-19, 2022 (virtual meeting).
Read more about
Click Here to Manage Email Alerts